Elevar Therapeutics announced that the US Food and Drug Administration has determined the PDUFA target approval date for its re-submitted new drug application for rivoceranib and carelizumab, which is intended for first-line systemic treatment of unresectable or metastatic hepatocellular carcinoma.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.